• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ocugen Inc (NQ: OCGN )

    1.035 +0.010 (+0.98%)
    Streaming Delayed Price Updated: 9:30 AM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 196,583
    Open 1.038
    Bid (Size) 1.030 (24)
    Ask (Size) 1.040 (20)
    Prev. Close 1.025
    Today's Range 1.030 - 1.040
    52wk Range 0.3450 - 2.105
    Shares Outstanding 257,328,085
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
    From Ocugen
    Via GlobeNewswire
    Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire

    Performance

    YTD
    +57.39%
    +57.39%
    1 Month
    -23.90%
    -23.90%
    3 Month
    -19.14%
    -19.14%
    6 Month
    -41.85%
    -41.85%
    1 Year
    +155.37%
    +155.37%

    More News

    Read More
    Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
    From Ocugen
    Via GlobeNewswire
    Peering Into Ocugen's Recent Short Interest
    Via Benzinga
    Why Ocugen (OCGN) Stock Is Falling
    Via Benzinga
    Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
    From Ocugen
    Via GlobeNewswire
    Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
    From Ocugen
    Via GlobeNewswire
    Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
    From Ocugen
    Via GlobeNewswire
    Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
    From Ocugen
    Via GlobeNewswire
    Ocugen (OCGN) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Ocugen Provides Business Update with Second Quarter 2024 Financial Results
    From Ocugen
    Via GlobeNewswire
    InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
    Via Investor Brand Network
    Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
    From Ocugen
    Via GlobeNewswire
    Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
    From Ocugen
    Via GlobeNewswire
    Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
    From Ocugen
    Via GlobeNewswire
    Ocugen, Inc. Announces Proposed Public Offering of Common Stock
    From Ocugen
    Via GlobeNewswire
    Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
    From Ocugen
    Via GlobeNewswire
    Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
    From Ocugen
    Via GlobeNewswire
    1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
    Via The Motley Fool
    3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
    Via InvestorPlace
    7 A-Rated Penny Stocks to Beat June Gloom
    Via InvestorPlace
    Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    3 Penny Stocks Set to Make New Millionaires in 2024
    Via InvestorPlace
    Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
    From Ocugen
    Via GlobeNewswire
    Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.